January 14, 2019 05:05 AM GMT



### **US Equity Strategy** | North America

# Weekly Warm Up: Don't Fear a Potential Recession; Embrace It

The S&P 500 reached our Bear Case (2400) late last year as we believe it embraced our earnings recession call. We expect upcoming negative data will prove 2600-2650 to be a good sale before a proper retest of the December lows. Wait for the retest and look to buy the cyclicals.

We always expected the S&P 500 to visit the low end of our consolidation range (2400-3000); however, we thought it would be in 1Q2019, not at the end of 2018. While there was a confluence of technical factors that conspired to create one of the worst Decembers in history, we also think the market embraced our earnings recession call as earnings revision breadth rolled over. In short, the market is discounting our out of consensus views on growth and it may have even discounted a modest economic recession.

Could our earnings recession turn into an economic one? Risks are rising, and we don't have a crystal ball, but we also don't really care about such an outcome if it's already priced. A few metrics we like to look at—y/y change in the S&P 500, PMIs, market implied pace of rate hikes (MSPOKE Index), front-end of the yield curve, and the Fed's recession probability models—have all signaled elevated risk of an economic recession. From an equity perspective, we think a retest of the December lows driven by more earnings and economic data disappointments would seal the deal on our earnings recession call. We are equity strategists, not economists, and we've said all along that an earnings recession amounts to the same thing as an economic one for investors.

Momentum: Defensive skew sending same message as the index. The long side of 3, 6, and 12 month momentum is very crowded in Defensives, while the short side skews heavily toward Cyclicals. The situation is especially concerning in short- and medium-term momentum strategies where nearly a fifth of the long side is in Staples, while nearly a third of the short side is in Energy. This is simply another example of the market anticipating the slowdown. Therefore, we want to buy Cyclicals if the market retests the December lows when cries for recession are likely to be loud, and irrelevant.

We are seeing early signs that our margin thesis is playing out. 2019 EBIT margin estimates have contracted by ~50 basis points since the beginning of October 2018. This is the most significant negative revision during this period (beginning Oct.-beginning Jan.) since the Financial Crisis. Both sales growth and earnings growth estimates for 2019 have also come down materially in conjunction with this margin estimate de-rate. We expect margin pressure to be a pervasive theme throughout 2019.

MORGAN STANLEY & CO. LLC

Michael J Wilson

EQUITY STRATEGIST

M.Wilson@morganstanley.com +1 212 761-2532

Adam Virgadamo, CFA

**EQUITY STRATEGIST** 

Adam.Virgadamo@morganstanley.com

+1 212 761-1376

Andrew B Pauker

EQUITY STRATEGIST Andrew.Pauker@morganstanley.com

+1 212 761-1330

+1 212 296-5254

Michelle M. Weaver

EQUITY STRATEGIST

Michelle.M.Weaver@morganstanlev.com

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.



## What to Focus on This Week

### No More Swishes

Calling the market's direction this past year reminds us of one of the greatest commercials of all time - 1993's The Showdown - where Michael Jordan and Larry Bird compete to make a series of successively harder shots through a basketball hoop. Their final shot attempt is "off the expressway, over the river, off the billboard, through the window, off the wall, nothing but net." After making a series of accurate calls in 2018, we realize it's only going to get harder in 2019. As such, we aren't calling "swish" at this point and we'll be happy if we can hit the rim.

As noted last week, we think the market completed its de-risking of our concerns late last year; specifically, tighter financial conditions and an earnings recession in 2019. Some sectors and stocks have even discounted a full blown economic recession, in our view. The bond market also appears to be in agreement regarding these concerns, having removed any further hikes by the Fed this year according to our proprietary market implied pace of rate hikes indicator.

When we published our outlook for 2019 in late November, we fully expected the S&P 500 to hit our bear case of 2400 sometime in the first half of 2019. We did not expect it to occur before year end 2018. We thought the market would need to actually see the earnings and economic data disappointments before reaching 2400. However, a confluence of exogenous events--perceptions of Fed miscommunication, Government shut down, poor year end liquidity and performance pressure--conspired to take the stock market to valuations we hadn't see since the post-Brexit reaction in 2016, culminating in what the press called the "Christmas Eve Massacre." Initially, it appeared as if equity markets sold off for technical reasons more than fundamental ones. However, on further inspection we think the market was simply pricing in the more growing risk of an earnings, and even an economic, recession. After all, if we could see that risk increasing, surely the market could too.

Sentiment and positioning also got washed out to levels we typically see during good buying opportunities. The issues we still need to deal with include the fact that we are in the midst of a fairly steep and broad negative earnings revision cycle, and there is significant technical resistance/overhead not far above current prices. From here, we think the risks are greatest at the stock level where either (1) valuations are still too high or (2) where earnings downside is even greater than what has been priced. (We published a stock screen last week as an example of how to begin looking for stocks with elevated risk). As we deal with these issues during 4Q earnings season and perhaps see some further deterioration in US economic data, we think the S&P 500 will suffer a re-test of the lows we experienced in December, but on less negative momentum and better breadth.


We've been vocal that we are aggressive buyers anytime we get near our bear case of 2400. So, if we actually suffer the re-test we are expecting, we would be buyers of that



almost regardless of what is going on, assuming it happens on less momentum and better breadth. We've also been advising clients to look at areas of the market that were hit the hardest and the earliest during last year's rolling bear market as a place to start. Our view is that we are likely to experience a rolling bottom as a prelude to the next bull market on a FIFO (first-in, first-out) basis. That means early cycle stocks and regions that tend to do well once a recession is priced.

To sum up, we think the broader market achieved our downside targets on valuation as well as on sentiment and positioning. However, the fundamentals remain murky at best with earnings visibility deteriorating and revisions decidedly negative at the moment. Economic data surprises have also turned negative and we think it could get worse in the near term, especially if the government shutdown persists. We are also wary of the significant overhead resistance created by the 4Q sell off, and the lack of a weekly positive divergence during the December capitulation (Exhibit 1). As such, 2600-2650 on the S&P 500 is a good level to start lightening up as we enter what is likely to be a period of negative news flow on earnings and the economy.

**Exhibit 1:** Nearby Technical Resistance/Overhead Is Formidable. We Did Not Get a Weekly Positive Divergence on December Sell Off, Suggesting a Re-Test Coming.



### How Are Markets Discounting Recession Probabilities?


While clients are aware of our Earnings Recession call for 2019, many have been asking us what happens if this turns into a full blown economic recession? The honest answer is that we don't know, but we're not convinced the distinction is that important for investors. Below, we show a few charts we think suggest the markets have already priced further deterioration in the data, and possibly a shallow economic recession.

First, the sell off in December brought the S&P 500 down almost 10% on a y/y basis, a very rare occurrence and something that historically has happened only when there is either an earnings recession, an economic recession, or both. In 2001-02 and 2008-09, the decline was much more severe but those were recessions accompanied by either a valuation bubble (2001-02) or a financial crisis (2008-09), neither of which we would expect this time around . We would argue that the next recession, whenever it arrives, will likely be more like the 1990 episode, shallow and brief. As you can see in Exhibit 2, the recent y/y decline in the S&P 500 is close to what we observed in 1990; and if we




get a full re-test and break as we expect in the next few months, it will likely be equivalent. In other words, between here and there, the S&P 500 would be pricing in our earnings recession and perhaps a shallow economic recession. Consistent with our 2019 earnings call, we are expecting the blue line in Exhibit 2 (NTM EPS growth) to rapidly catch-up (to the downside) to the yellow line (price change) as markets lead the fundamentals. We suspect such rapid decline in forward earnings will provide a reason for stocks to revisit the December lows, but of course, that's the trap and the time to buy, not sell.

Exhibit 2: Recent Decline in the S&P 500 Suggests A Steep Fall in Earnings Growth Is Imminent



Second, the December manufacturing PMI showed the largest decline since 2008, the beginning of the last economic recession in the US. As noted last week, part of the reason why the S&P 500 sold off so sharply in November and December was that it anticipated the PMIs were about to roll. Exhibit 3 below plots the S&P y/y vs. the ISM Manufacturing PMI and shows a pretty tightly linked relationship. In fact, based on the 10% y/y decline in the S&P 500 in December, we should expect a break of 50 on the downside for the Manufacturing PMI which implies an economy that is slowing and maybe even contracting--i.e., a recession. Once again, such a collapse in the manufacturing PMI would provide another reason for the re-test of the lows and a time to buy, not sell.

Exhibit 3: PMIs vs. S&P Y/Y - The December Lows Discount Some Contraction Readings



Source: Bloomberg, Morgan Stanley Research



Fixed Income Markets - Likelihood of Rate Cuts and Front End of the Curve

In addition to equities, we are also paying attention to signals from fixed income markets. Specifically, the implied path of rate hikes/cuts and front end of the yield curve.

One of the more intuitive tools we have for looking at what fixed income markets are saying regarding the path for the Fed is **our Rates Strategy team's MSPOKE Index which simply shows the number of Fed hikes/cuts implied by the fixed income markets over the next twelve months** (Exhibit 4). Here too, we are currently testing the 2015/16 lows following one of the more rapid declines in the series. As recently as November, the market was pricing in 3 hikes and on January 3rd it was down to almost pricing in one full *cut* (difficult to see on monthly time series below). Looking at the S&P y/y vs. this index, we can see the track record is mixed - sometimes leading, sometimes coincident.

We would argue that much of the most recent drop in the MSPOKE was market and volatility driven--i.e. tightening financial conditions--which means there is a bit of circularity in this signal. If the fixed income market's read is that the Fed is reacting to lower equities and higher volatility, and if the Fed's subsequent dovish tone helps calm equity markets, does the rebound in equities then give the Fed room to become incrementally more hawkish? Chair Powell's greater willingness to consider a pause in rate hikes and balance sheet reduction has undoubtedly helped to bring some stabilization to the markets including the expected path of rate hikes/cuts over the next 12 months. However, should the hard data deteriorate further, as we expect, we think the markets will quickly return to pricing in a recession and rate cuts much like it did at the end of the year and very early in 2019. In other words, a more dovish Fed likely can't prevent an earnings or economic recession at this point if the die has already been cast.




Exhibit 4: A Retest of S&P Lows Should More Than Match Fixed Income Market Bearishness

Source: Bloomberg, Morgan Stanley Research.



One of our other preferred signals is watching for inversion at the front end of the curve - the spread between the 2-year yield and the Fed Funds rate. Exhibit 5 shows this spread since the start of 2015. We prefer to focus on the short end of the curve because inversion here is a very strong signal from the bond market that over the next two years, the Fed Funds rate is moving lower. With every hike in the Fed Funds rate, the spread mechanically moves lower, but over the last two years, the spread has generally recovered to within a narrow range. With this last Fed hike, the spread plummeted and even saw a modest inversion for the first time since 2011--the last time we had a true economic recession scare. Though this part of the curve is (just barely) no longer inverted, the signal bears close watching.

1.00 2.25 0.75 1.75 1.25 1 0.00 0.75 0.25 2s-FFs Spread (Ihs) FF Upper Bound (rhs)


Exhibit 5: 2s - Fed Funds Spread Recovering Post Inversion, But Signal Getting Louder

Recession Probability Rising to Highest Levels Since the Crisis

Source: Bloomberg, Morgan Stanley Research

A final metric we highlight here is the NY Fed's model showing the probability of recession in the next 12 months. As shown in Exhibit 6, this is hardly a precision instrument, but directionally, it does give some idea on when a cycle may be nearing its end. The metric has been on the rise for the last two years and now sits at post-crisis highs. The fact that this metric is higher than it was during the last earnings recession in 2015-16, suggests the risk of an economic recession this time around is greater and aligns with our view that the market's sell off in December was justified for fundamental reasons and there is a good chance we aren't out of the woods. Including the most recent spike, this metric has reached a level this high 11 times going back to 1955. Only 3 (27%) of those occasions (1965, 1996, 1999) were associated with a false positive, while 8 (73%) led to a full blown economic recession.

Exhibit 6: Recession Probability Risk Highest Since 2006. Only 27% Chance it's a False Positive



The bottom line for us is that we don't know if an economic recession is coming or not. However, that's not really the important question for investors. Our economics team has been much more bearish on US growth than the consensus and they are modeling a severe deceleration in US GDP growth from 4.2% in 2Q18 to 1% in 3Q19. While that's technically not a recession, that kind of deceleration will feel like a recession to the market and will help our earnings recession call come to fruition--which is really what matters to us, and the market. In other words, by the time investors figure out we are in a recession it may be too late to do anything about it and, quite frankly, it's more likely time to buy than sell. Investors need to anticipate rather than react.

Given the swift and steep decline in the stock market, the ISM, and the front end of the yield curve, we think the odds of an earnings and economic recession have increased materially. Once again, that's not really what's important. Instead, focus on the fact that the market is discounting a real fall in earnings growth which now looks obvious even to the casual observer and the media. In that context, we think it's premature to blow the all clear whistle as earnings appear likely to come down sharply over the next month. As such, we want to wait for the re-test at which point the calls for recession will likely be louder, and irrelevant.

### Momentum Weights A Bit Unbalanced

This week, we take a look at the composition of 3, 6, and 12 month momentum strategies – the 3 and 6 month groups have no lag while the 12 month version has a 1 month lag. The tables below show sector weights for the different versions of momentum vs. market weight which is based off of the Russell 3000 (Exhibit 7 and Exhibit 8).

Should it materialize by the end of 1Q, a short term cyclical bounce would likely cause a violent move in momentum: the long side of all versions of momentum is very crowded in Defensives while the short side skews heavily toward Cyclicals. The situation is especially concerning in short and medium term momentum strategies where nearly a fifth of the long side is in Staples while nearly a third of the short side is Energy. Even if investors employ a sector cap in their strategy, those caps are likely "maxed" out on either side of the Cyclical/Defensive spectrum.

Sector and Industry Group Details



Over both the short and medium term, Consumer Staples is a massive overweight in long momentum (23.4% in 3 month and 18.8% in 6 month vs. a 6.5% weight in the Russell 3000). Utilities is very overweight over the short term and moderately overweight in the medium term (15.1% in 3 month and 5.3% in 6 month vs. a market weight of 3.2%). Energy is a huge underweight across all time horizons with near 0% weights. It is also a major component of the short momentum bucket; its weight is ~30% in 3 and 6 month momentum while it is 11% in 12 month momentum. Tech is also a substantial underweight across the board on the long side.

On the long side, Financials are very underweight over the long term and short term and are slightly underweight over the medium term. A lot of this has to do with banks; its weight is near zero across the different horizons. However, Financials have little representation on the short side and have not been among the worst performers.

Health Care is a very big component of long 6 and 12 month momentum (35% in 6 month and 25% in 12 month vs. a 15% weight in the Russell 3000). This overweight has been driven by Pharma, the most defensive part of the sector. Its weight has faded recently and is now just below market weight though Pharma is still overweight. If politicians focus on Health Care and drug pricing as a key issue in 2019 that could potentially create problems for healthcare stocks.

The dramatic skew toward defensively oriented sectors and stocks over the past 3-6 months is just another piece of evidence that the market is very nervous about growth. Once again, that is a good thing and supports our view that a lot of bad news has already been priced. Once again, as the hard data deteriorates and is explicitly revealed, we expect equity prices to revisit the December lows. As noted above, we want to buy that decline and we want to lean toward the more cyclical parts of the market and lighten up on the defensive areas. We think the relative outperformance of cyclicals versus defensives during the most recent rally is indicative of this underlying momentum shift. On that note, we would not be chasing cyclicals here because they have bounced too much near term and are likely to underperform on a re-test of the broader equity market.

**Exhibit 7:** Long Momentum Composition by Time Horizon

Long Momentum									
Sector	3 Month	6 Month	12 Month	Market Weight					
Communication Services	8.4%	5.8%	13.1%	9.3%					
Consumer Discretionary	11.6%	8.5%	38.2%	10.6%					
Consumer Staples	23.4%	18.8%	3.4%	6.5%					
Energy	0.2%	0.0%	0.5%	5.2%					
Financials	4.3%	12.6%	0.8%	13.8%					
Health Care	14.2%	35.0%	24.9%	14.8%					
Industrials	2.4%	3.2%	2.8%	10.0%					
Information Technology	11.3%	6.9%	14.6%	19.7%					
Materials	1.0%	0.7%	0.5%	3.0%					
Real Estate	8.1%	3.2%	0.4%	3.8%					
Utilities	15.1%	5.3%	0.8%	3.2%					
	Overweight:		Underweight:						



Exhibit 8: Short Momentum Composition by Time Horizon

Short Momentum									
Sector	3 Month	6 Month	12 Month	Market Weight					
Communication Services	9.0%	9.1%	2.8%	9.3%					
Consumer Discretionary	10.3%	11.8%	14.9%	10.6%					
Consumer Staples	2.9%	2.5%	9.3%	6.5%					
Energy	30.6%	28.3%	11.2%	5.2%					
Financials	2.6%	2.0%	9.9%	13.8%					
Health Care	10.9%	8.6%	14.1%	14.8%					
Industrials	8.3%	12.1%	16.1%	10.0%					
Information Technology	22.0%	17.7%	13.9%	19.7%					
Materials	2.2%	4.6%	4.5%	3.0%					
Real Estate	0.2%	2.2%	0.8%	3.8%					
Utilities	1.1%	1.0%	2.7%	3.2%					

Source: Bloomberg, Morgan Stanley Research

### Margin Estimates Are Deteriorating

Overweight:

In No Margin for Error (October 11, 2018), we laid out the case for operating margin deterioration in 2019 as macro cost pressures build and demand slows. We viewed 2019 consensus EBIT margin estimates as being overly optimistic and expected downward revisions to occur. As Exhibit 9 shows, EBIT margin estimates have declined by ~50 basis points since the beginning of October 2018 (when 3Q earnings season began in earnest). Expectations for 2019 operating margins are now just slightly higher vs. 2018 margins (Exhibit 10). We view this as a positive development and it helps set the stage for a more durable low when we re-test the lows.

**Exhibit 9:** 2019 EBIT Margin Estimates Have Declined Materially Since Early October



**Exhibit 10:** 2019 EBIT Margin Estimates Now Expected to be Just Slightly Higher Vs. 2018

Underweight:




Source: FactSet, Morgan Stanley Research as of January 9, 2019.

Exhibit 11 shows that this downward revision in margin estimates is the most significant since the Financial Crisis. While this decline has been severe, we expect further cuts from analysts as we receive full year guidance from companies during 4Q earnings season. This dynamic of rolling margin/EPS estimate cuts should continue throughout 2019—a typical development during earnings contractions. As Exhibit 12 illustrates, the cut to EBIT margin estimates since early October has been largely driven by Energy, Communication Services and Tech. Within Communication Services, negative revisions




were concentrated in the Tech-oriented stocks as opposed to the Media-oriented ones. Once again, such a speedy decline in these estimates is a good thing and we would compare it to ripping off a bandage. It's better to just get it over with.

**Exhibit 11:** The Negative Revision in Next Calendar Year EBIT Margins We Have Seen Since Early October Is the Worst Since the Financial Crisis



Source: FactSet, Morgan Stanley Research as of January 9, 2019.

**Exhibit 12:** This Negative Revision Has Been Driven by Energy, Comm Services, and Tech 2019 EBIT Margin % Change from Start of 3Q EPS Season - Today



Source: FactSet, Morgan Stanley Research as of January 9, 2019.


This downward revision in margins has coincided with a downward revision in EPS growth from 10.4% at the start of October to 6.5% today (Exhibit 13). Sales growth estimates for 2019 have also declined since the start of 3Q earnings season (Exhibit 14). However, as recently as two weeks ago, they were still flat relative to where they were at the start of 2018. In conjunction with our bearish margin call, we have been highly skeptical that sales growth could rise at a mid single digit clip in 2019 given that our economists have called for US GDP growth to slow so meaningfully in 2019 as already discussed above.

As Exhibit 14 shows, sales growth estimates took another leg down since the beginning of January 2019. A big driver here was Apple's guidance cut (2019 sales growth expectations went from 4.5% on Jan. 2 to -2.3% on Jan. 10). We are doubtful that AAPL's




cut is an isolated incident given our pessimistic view on demand and margins for 2019. Thus, we would expect negative guidance revisions to be a persistent theme during 4Q earnings season. We would expect AAPL-like price reactions to guidance cuts in stocks where relative valuations remain elevated vs. history (i.e., a cyclical slowdown is not priced). Many of these equities are concentrated in Tech, Comm Services and pockets of Consumer Discretionary. Exhibit 15 and Exhibit 16 show the sector-level drivers of 2019 EPS and sales growth revisions since the start of 3Q earnings season. Energy, Comm Services and Tech have been negative drivers of the '19 earnings growth estimate. Energy, Tech and Financials have been negative drivers of the 2019 sales growth estimate.

**Exhibit 13:** Downward EBIT Revisions Have Coincided with Downward EPS Revisions




Source: FactSet, Morgan Stanley Research as of January 9, 2019.

**Exhibit 14:** Negative Sales Growth Revisions Have Accelerated Recently



Source: FactSet, Morgan Stanley Research as of January 9, 2019

**Exhibit 15:** Energy, Comm Services and Tech Also Driving Downward EPS Revision Story



Source: FactSet, Morgan Stanley Research as of January 11, 2019.

**Exhibit 16:** Energy, Tech and Financials Fueling Downward Sales Growth Revision Story



 $Source: Fact Set, Morgan\ Stanley\ Research\ as\ of\ January\ 11,\ 2019.$ 

Note: Slight adjustments were made to constituents due to mergers since we previously published margin charts. As a result, absolute margin levels are slightly different.



# Fresh Money Buy List - Updates

Each week, we will use a section of our Weekly Warm Up to provide brief updates on select stocks on our Fresh Money Buy List.

Exhibit 17: Fresh Money Buy List - Stats and Performance

Company Name	Ticker	MS Analyst	Sector	Market Cap	Price MS PT	MS PT % to MS	MS Analyst	Date	Total Return Since Inclusion		
Company Name	Herei	Rating	Sector	(\$Bn)	FIICE	WIS F I	PT	INIS Allalyst	Added	Absolute	Rel. to S&P
Walt Disney Co	DIS	Overweight	Communication Services	\$168.3	\$112.65	\$135.00	20%	Swinburne, Benjamin	3/14/2018	10.3%	14.9%
Humana Inc	HUM	Overweight	Health Care	\$39.2	\$283.47	\$418.00	47%	Sopcak, Zack	7/19/2018	(10.3%)	(3.4%)
Iqvia Holdings Inc	IQV	Overweight	Health Care	\$25.4	\$122.81	\$145.00	18%	Goldwasser, Ricky	3/14/2018	16.2%	20.8%
LyondellBasell Industries N.V.	LYB	++	Materials	\$33.9	\$86.00	++	++	Andrews, Vincent	3/14/2018	(19.8%)	(15.2%)
Microsoft	MSFT	Overweight	Information Technology	\$799.1	\$102.80	\$130.00	26%	Weiss, Keith	3/14/2018	10.3%	14.8%
NextEra Energy Inc	NEE	Overweight	Utilities	\$84.8	\$175.71	\$184.00	5%	Byrd, Stephen	3/14/2018	15.9%	20.4%
Occidental Petroleum Corp	OXY	Overweight	Energy	\$50.1	\$66.22	\$73.00	10%	McDermott, Devin	7/19/2018	(18.4%)	(11.5%)
Progressive Corp	PGR	Overweight	Financials	\$36.2	\$61.68	\$84.00	36%	Pan, Kai	12/3/2018	(7.0%)	(1.2%)
T-Mobile US, Inc.	TMUS	++	Communication Services	\$59.01	\$69.00	++	++	Flannery, Simon	3/14/2018	6.2%	10.8%
Current List Performance											
Average (Eq. Weight)				\$144.0			23%			0.4%	5.6%
Median				\$50.1			20%			6.2%	10.8%
% Positive Returns (Abs. / Rel.)										56%	56%
% Negative Returns (Abs. / Rel.)										44%	44%
Avg. Hold Period (Months)											8.2
All Time List Performance											
Average (Eq. Weight)										(1.5%)	1.5%
Median										(4.6%)	(1.2%)
% Positive Returns (Abs. / Rel.)										46%	46%
% Negative Returns (Abs. / Rel.)										54%	54%
Avg. Hold Period (Months)											7.7

<sup>++</sup> Rating and other information has been removed from consideration in this report because, under applicable law and/or Morgan Stanley policy. Morgan Stanley may be precluded from issuing such information with respect to this company at this time.

Performance returns shown above represent local currency total returns, including dividends and excluding brokerage commission. Returns are calculated using the closing price on the last trading day before the date shown in the "Date Added" column through close on the last trading day prior to publication of this report for stocks currently on the list and through close on the day of removal for stocks formerly on the list. These figures are not audited. Past performance is no guarantee of future results.

Source: Bloomberg, Morgan Stanley Research,

### Microsoft (MSFT), Keith Weiss

• CIO Survey Gives Confidence Secular Can Trump the Cyclical at Microsoft - Our 4Q18 AlphaWise CIO Survey shows impressive spending intentions for Microsoft's cloud and on-premise solutions, with CIOs' expectations for on-premise server products improved vs. prior surveys and Microsoft well positioned to garner IT budget share with shift to Public Cloud. Reiterate OW.

### NextEra Energy (NEE), Stephen Byrd

- 2019 Outlook: Investor Feedback on our Views We highlighted NEE as a potential beneficiary in the event of a market downturn, as well as offering strong growth prospects at reasonable valuations. We found that investors are concerned about longer-term wind market growth for NEE particularly in light of the stock's premium valuation. We believe the market under-appreciates the magnitude of future US wind growth, given significant improvement in wind turbine technology, and we believe NEE will continue to be the leader in generating significant shareholder value from wind project development.
- Monthly Meter Reading Price target lowered to \$184 from \$194 as MS coverage



multiples were marked to market.

### T-Mobile US (TMUS), Simon Flannery

• T-Mobile Prereleases Strong 4Q Subscriber Performance - T-Moblie prereleased 4Q18 subscriber results that were ahead of expectations. The 2.4m net adds were the highest in T-Mobile's history, while the 1.4m postpaid net adds was the best 4Q ever, and the 1.0m phone net adds was the best 4Q performance in four years. Importantly, postpaid phone churn (0.99%) was down 19 bps Y/Y, and below 1.0% for the second time this year, and 5 bps better than consensus (1.04%).




# Weekly Charts to Watch

Exhibit 18: Four Charts to Focus On











Source: FactSet, Bloomberg, Robert Shiller, Morgan Stanley Research. Top two and bottom right: As of December 31, 2018. Bottom left: As of January 10, 2019. MS Leading Earnings Indicator is a macro factor based earnings model that leads actual earnings growth by one year with a 0.7 12-month leading correlation. Note: S&P 500 fundamental data used post March 1993; Top 500 by market cap data used before 1993. LTM equity risk premium average is since 1920. ERP based on forward earnings yield and 10-year Treasury Yield.

**UPDATE** 

### Exhibit 19: US Earnings Snapshot



### S&P 500 NTM EPS vs. Total Return Level



### S&P 500 Earnings Revisions Breadth



S&P 500 Earnings Revisions Breadth

	Current N	TM EPS Revi	sions Vs. Pr	ior Periods
Sector/Index	3/31/2017	6/30/2017	9/30/2017	12/31/2017
S&P 500	27.6%	23.6%	21.2%	17.0%
Comm Services	29.7%	28.9%	24.9%	21.8%
Consumer Discretionary	22.7%	20.0%	20.2%	20.0%
Consumer Staples	12.2%	9.9%	7.2%	5.3%
Energy	50.3%	47.5%	59.7%	32.7%
Financials	32.1%	28.3%	25.8%	20.2%
Health Care	23.9%	21.0%	18.3%	17.1%
Industrials	28.6%	21.8%	20.5%	22.7%
Info Tech	30.7%	24.3%	19.3%	12.0%
Materials	28.3%	23.8%	19.9%	13.4%
Utilities	13.4%	11.3%	9.4%	7.9%
Real Estate	6.4%	4.8%	3.3%	2.1%

Source: Thomson Financial, FactSet, Morgan Stanley Research. Top: L: As of January 11, 2019 R: As of January 3, 2019 Bottom: L: As of January 9, 2019. R: As of January 10, 2019.



### Exhibit 20: US Equity Market Traditional Valuation Measures

### S&P 500 NTM P/E -S&P 500 NTM P/E S&P 500 NTM P/E Avg.


### S&P 500 NTM P/S



### S&P 500 LTM P/B



### S&P 500 LTM EV/EBITDA




Source: FactSet, Morgan Stanley Research as of December 31, 2018. Monthly Data. Note: S&P 500 fundamental data used post March 1993; Top 500 by market cap data used before 1993.

UPDATE

Exhibit 21: US Equity Market Technicals and Financial Conditions


# S&P 500 Cumulative Advance-Decline ——Bloomberg Cumulative Advance-Decline Line for S&P 500 55,000 45,000 25,000 5,000 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019

### S&P 500 with Moving Averages



Source: Bloomberg, Morgan Stanley Research. All: As of January 10, 2019

### S&P 500 Percent Members Above 200-Day Moving Average




### Morgan Stanley Financial Conditions Index





**UPDATE** 

Exhibit 22: US Equity Market Sentiment











Source: Bloomberg, Factset, Morgan Stanley Research. As of January 11, 2019.


### **UPDATE**

### Exhibit 23: US Small Cap Equities





### Russell 2000 Relative Earnings Revisions Breadth





Russell 2000 Relative Performance vs. S&P 500



Source: Factset, Morgan Stanley Research. Top Right and Bottom Left: As of December 31, 2018. Top Left and Bottom Right: As of January 10, 2019.

Exhibit 24: We Have a Year End 2019 Price Target of \$2,750

# Morgan Stanley S&P 500 Price Target: Year End 2019

Landscape	Earnings	Multiple	Price Target	Upside / Downside
Bull Case	\$185	16.0x	3,000	15.5%
Base Case	\$176	15.5x	2,750	5.9%
Bear Case	\$161	15.0x	2,400	-7.6%

Current S&P 500 Price as of: 2,597 1/10/2019


Source: Morgan Stanley Research

Exhibit 25: Sector Recommendations

Morgan Stanley Sector Recommendations								
Overweight	Consumer Staples	Energy	Financials	Utilities				
Neutral	Comm Services	Health Care	Industrials	Materials	Real Estate			
Underweight	Discretionary	Technology						


Source: Morgan Stanley Research





 $Source: Factset, Morgan \ Stanley \ Research. \ As \ of \ January \ 9, 2019. \ Sectors \ with \ *use \ current, \ fixed \ constituents. \ Source: Factset, \ Morgan \ Stanley \ Research. \ As \ of \ January \ 9, 2019. \ Sectors \ with \ *use \ current, \ fixed \ constituents. \ As \ of \ January \ 9, 2019. \ Sectors \ with \ *use \ current, \ fixed \ constituents.$ 

### Exhibit 27: US Sector NTM EPS vs. Total Return Level



For valuation methodology and risks associated with any price targets referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

Morgan Stanley & Co. LLC ("Morgan Stanley") is acting as financial advisor to Deutsche Telekom AG ("DT") and is providing financing services in relation to T-Mobile USA, Inc. ("T-Mobile") for the proposed acquisition by T-Mobile of Sprint Communications, Inc. ("Sprint") as announced on 29th April 2018. The transaction is subject to approval by T-Mobile and Sprint shareholders and other customary closing conditions. DT and T-Mobile have agreed to pay fees to Morgan Stanley for its financial services that are contingent upon the consummation of the transaction. Please refer to the notes at the end of the report.

Morgan Stanley is acting as financial advisor to LyondellBasell Industries NV ("LyondellBasell") in connection with its exclusive discussions with Odebrecht S.A. regarding a potential transaction between LyondellBasell and Braskem, S.A., as announced on June 15, 2018. There is no guarantee that any transaction will ultimately be consummated. Morgan Stanley may receive compensation from LyondellBasell for its services. Please refer to the notes at the end of this report.



### **Disclosure Section**

The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. LLC, and/or Morgan Stanley C.T.V.M. S.A., and/or Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., and/or Morgan Stanley Canada Limited. As used in this disclosure section, "Morgan Stanley" includes Morgan Stanley & Co. LLC, Morgan Stanley C.T.V.M. S.A., Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., Morgan Stanley Canada Limited and their affiliates as necessary.

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

### **Analyst Certification**

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Andrew B Pauker; Adam Virgadamo, CFA; Michelle M. Weaver; Michael J Wilson.

Unless otherwise stated, the individuals listed on the cover page of this report are research analysts.

### **Global Research Conflict Management Policy**

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictpolicies. A Portuguese version of the policy can be found at www.morganstanley.com.br

### Important US Regulatory Disclosures on Subject Companies

As of December 31, 2018, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: LyondellBasell Industries N.V., NextEra Energy Inc, Occidental Petroleum Corp, Walt Disney Co.

Within the last 12 months, Morgan Stanley managed or co-managed a public offering (or 144A offering) of securities of NextEra Energy Inc, Progressive Corp, T-Mobile US, Inc..

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Humana Inc, NextEra Energy Inc, Progressive Corp, Walt Disney Co.

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Humana Inc, Iqvia Holdings Inc, LyondellBasell Industries N.V., Microsoft, NextEra Energy Inc, Occidental Petroleum Corp, Progressive Corp, T-Mobile US, Inc., Walt Disney Co. Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from Humana Inc, Iqvia Holdings Inc, LyondellBasell Industries N.V., Microsoft, NextEra Energy Inc, Occidental Petroleum Corp, Progressive Corp, T-Mobile US, Inc., Walt Disney Co.

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Humana Inc, Iqvia Holdings Inc, LyondellBasell Industries N.V., Microsoft, NextEra Energy Inc, Occidental Petroleum Corp, Progressive Corp, T-Mobile US, Inc., Walt Disney Co.

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: Humana Inc, Iqvia Holdings Inc, LyondellBasell Industries N.V., Microsoft, NextEra Energy Inc, Occidental Petroleum Corp, Progressive Corp, T-Mobile US, Inc., Walt Disney Co.

Morgan Stanley & Co. LLC makes a market in the securities of Iqvia Holdings Inc, LyondellBasell Industries N.V., Microsoft, NextEra Energy Inc, Occidental Petroleum Corp, Progressive Corp, T-Mobile US, Inc., Walt Disney Co.

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

### STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

### **Global Stock Ratings Distribution**

(as of December 31, 2018)

The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm. For disclosure purposes only (in accordance with NASD and NYSE requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.



	COVERAGE UI	NIVERSE	INVESTMENT BANKING CLIENTS (IBC)			OTHER MATERIAL INVESTMENT SERVICES CLIENTS (MISC)	
STOCK RATING	COUNT	% OF	COUNT	% OF	% OF	COUNT	% OF
CATEGORY		TOTAL		TOTAL IBC	RATING		TOTAL
				(	CATEGORY		OTHER
							MISC
Overweight/Buy	1143	36%	282	40%	25%	540	38%
Equal-weight/Hold	1428	45%	336	47%	24%	651	46%
Not-Rated/Hold	46	1%	6	1%	13%	6	0%
Underweight/Sell	566	18%	86	12%	15%	232	16%
TOTAL	3,183		710			1429	

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the "% of total" column may not add up to exactly 100 percent.

### **Analyst Stock Ratings**

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

### **Analyst Industry Views**

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

### Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC or Morgan Stanley or any of their affiliates, are available on the Morgan Stanley Wealth Management disclosure website at www.morganstanley.com/online/researchdisclosures. For Morgan Stanley specific disclosures, you may refer to www.morganstanley.com/researchdisclosures.

Each Morgan Stanley Equity Research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the Equity Research report on behalf of Morgan Stanley. This could create a conflict of interest.

### **Other Important Disclosures**

Morgan Stanley & Co. International PLC and its affiliates have a significant financial interest in the debt securities of Humana Inc, LyondellBasell Industries N.V., Microsoft, Occidental Petroleum Corp, Progressive Corp, T-Mobile US, Inc., Walt Disney Co.

Morgan Stanley Research policy is to update research reports as and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions. Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix. Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.

Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (http://www.morganstanley.com/terms.html). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use

(http://www.morganstanley.com/terms.html). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy\_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy\_pledge.html).

If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies



please do not access our research.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

The "Important US Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.

To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non-customer reader within the scope of Article 7-1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A. located at Av. Brigadeiro Faria Lima, 3600, 6th floor, São Paulo - SP, Brazil; and is regulated by the Comissão de Valores Mobiliários; in Mexico by Morgan Stanley México, Casa de Bolsa, S.A. de C.V which is regulated by Comision Nacional Bancaria y de Valores. Paseo de los Tamarindos 90, Torre 1, Col. Bosques de las Lomas Floor 29, 05120 Mexico City; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd. in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Morgan Stanley Asia International Limited, Hong Kong Branch; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Morgan Stanley Asia International Limited, Singapore Branch (Registration number T11FC0207F); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch, in India by Morgan Stanley India Company Private Limited; in Indonesia by PT. Morgan Stanley Sekuritas Indonesia; in Canada by Morgan Stanley Canada Limited, which has approved of and takes responsibility for its contents in Canada; in Germany by Morgan Stanley Bank AG, Frankfurt am Main and Morgan Stanley Private Wealth Management Limited, Niederlassung Deutschland, regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin); in Spain by Morgan Stanley, S.V., S.A., a Morgan Stanley group company, which is supervised by the Spanish Securities Markets Commission (CNMV) and states that Morgan Stanley Research has been written and distributed in accordance with the rules of conduct applicable to financial research as established under Spanish regulations; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulatory Authority and regulated by the Financial Conduct Authority and the Prudential Regulatory Authority, disseminates in the UK research that it has prepared, and approves solely for the purposes of section 21 of the Financial Services and Markets Act 2000, research which has been prepared by any of its affiliates. RMB Morgan Stanley Proprietary Limited is a member of the JSE Limited and regulated by the Financial Services Board in South Africa. RMB Morgan Stanley Proprietary Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. The information in Morgan Stanley Research is being disseminated by Morgan Stanley Saudi Arabia, regulated by the Capital Market Authority in the Kingdom of Saudi Arabia, and is directed at Sophisticated investors only.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client. The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail



Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations. The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P. Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley. Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework.

© 2019 Morgan Stanley